Safety Update: Kaftrio Psychological Side Effects The MHRA has issued a safety update regarding psychological side effects reported in patients with cystic fibrosis treated with Kaftrio. While these effects are infrequent, healthcare professionals should be aware of the risk profile and monitor patients accordingly. Key Points Psychological side effects including anxiety, low mood, sleep disturbance, […]
MHRA Alert – SABA Overuse in Asthma: Safety Reminder and Prescribing Guideline Changes
MHRA Safety Reminder: Short-Acting Beta 2 Agonist Overuse Healthcare professionals and patients are reminded of the significant risks associated with overuse of short-acting beta 2 agonists (SABA) in asthma management. The MHRA has issued this alert to reinforce existing safety guidance and highlight recent changes to SABA prescribing recommendations. Key Safety Points Overuse of SABA—with […]
MHRA Alert – Fezolinetant (Veoza): Liver Injury Risk & Monitoring Guidance
Drug Safety Update: Fezolinetant (Veoza) The MHRA has issued new safety recommendations for fezolinetant (Veoza) following reports of drug-induced liver injury in patients receiving this treatment. Healthcare providers should be aware of this risk and implement appropriate monitoring protocols. Key Points Fezolinetant treatment carries a documented risk of drug-induced liver injury New recommendations have been […]
MHRA Alert – January 2025 Medicine Recalls and Safety Notifications
January 2025 MHRA Safety Update The MHRA has published a summary of letters and notifications issued to healthcare professionals during January 2025 concerning medicines and medical devices. This update consolidates recent safety communications to help you stay informed of regulatory actions affecting clinical practice. What You Need to Know This alert covers a range of […]